Alnylam Pharmaceuticals (ALNY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ:ALNY) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has several drugs already on the market, the biopharma is not yet profitable.But if Alnylam can gain expedited approval from the FDA for its RNA interference drug vutrisiran, that could change quickly. Alnylam stock soared 31% on positive Phase 3 trial news and continued rising afterward. Getting vutrisiran, which is m ...

Could Alnylam Pharmaceuticals (NASDAQ:ALNY) become a household name in 2024? At the very least, the company should be well known in the medical community. If you like to wager small amounts of money on biotechnology stocks, then you really ought to consider Alnylam Pharmaceuticals stock.As we’ll discuss in a moment, Alnylam Pharmaceuticals didn’t start off 2024 with perfect financials. However, a recent announcement indicates a breakthrough moment for Alnylam Pharmaceuticals and, potentially, for some heart ...

Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market value of the ecosystem should be massive. Grand View Research estimates that it would be worth $3.88 trillion by 2030. Still, the opportunistic investor may want to consider cheap biotech stocks.It comes down to adding more pieces on the table. You can always elect the high-flying names that command rich multiple p ...

UKRAINE - 2021/05/27: In this photo illustration, the Alnylam Pharmaceuticals logo seen on a ... [+] smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesAlnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial ...

Core Viewpoint - Alnylam Pharmaceuticals achieved a new 52-week high following positive results from the phase III HELIOS-B study of Amvuttra (vutrisiran), leading to a 34.5% increase in stock price [1]. Group 1: Study Results - The HELIOS-B study met its primary endpoint, showing a statistically significant reduction in all-cause mortality and recurrent cardiovascular events in both the overall and monotherapy populations [2]. - Statistically significant improvements were observed across all secondary endpoints, including key measures of disease progression at Month 30 [2]. - Vutrisiran reduced all-cause mortality in both populations up to Month 42, based on a pre-specified intent-to-treat analysis [2]. Group 2: Patient Population and Safety - The study enrolled 655 adult patients with ATTR amyloidosis and cardiomyopathy, who received either vutrisiran or placebo [3]. - Vutrisiran demonstrated a favorable safety and tolerability profile, with adverse event rates similar to the placebo group [4]. Group 3: Market Potential and Financial Performance - Alnylam plans to submit global regulatory applications starting in late 2024, aiming for vutrisiran to become the new standard of care for ATTR amyloidosis with cardiomyopathy [4]. - Amvuttra generated $195 million in sales in Q1, reflecting a 92% increase, driven by new patient uptake and switches from Onpattro [5].

Key TakeawaysAlnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events.The biopharmaceutical company said it would be seeking regulatory approval later this year, including asking the Food and Drug Administration for a priority review.The news sent shares of Alnylam soaring over 31% in early trading Monday. Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday afte ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates >Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Shares of the biopharmaceutical company are now trading at a year-to-date high of $220.  Why is it significant for Alnylam Pharmaceuticals stock?Copy link to sectionVutrisiran de ...

Company Overview - Alnylam Pharmaceuticals (ALNY) shares increased by 5.3% to $165.70, with a notable trading volume, reflecting a 5.4% gain over the past four weeks [1][2] - The rise in stock price is attributed to investor optimism regarding Amvuttra's (vutrisiran) revenue potential, which recorded sales of $195 million in Q1 2024, a 92% increase [2] Financial Performance - Alnylam is expected to report a quarterly loss of $0.78 per share, representing a year-over-year change of +64.7%, with revenues projected at $450.23 million, up 41.3% from the previous year [3] - The consensus EPS estimate has been revised slightly higher in the last 30 days, indicating a positive trend that may lead to stock price appreciation [3] Industry Context - Alnylam operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Acadia Pharmaceuticals (ACAD), whose stock rose by 3.7% to $15.30 [4] - Acadia's consensus EPS estimate has decreased by 2.8% over the past month, but shows a significant year-over-year change of +1500% [4]

Editor's note: Seeking Alpha is proud to welcome SA's Undercovered Dozen Series as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » cassp/E+ via Getty Images Introduction There's lots to like in our first weekly edition of The "Undercovered" Dozen. We'll be presenting ideas that were published during June 1st - 6th. So f ...